Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-09-08 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司持股5%以上股东集中竞价减持计划完成暨减持结果公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a large shareholder's share reduction plan through centralized bidding. It details the shareholder's holdings before and after the reduction, the number of shares reduced, the reduction period, and the prices involved. The content focuses on shareholding changes by a significant shareholder (over 5%) and the completion of a planned share sale. There are no financial statements, earnings data, or management discussions. The document fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2022-09-08 Chinese
长春百克生物科技股份公司关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Changchun Baker Biological Technology Co., Ltd. regarding the delay of certain projects funded by raised capital. It details the original and adjusted timelines for project completion, reasons for delays including COVID-19 and regulatory approvals, and confirms that the changes do not affect the investment amount or project scope. The document includes opinions from independent directors, the supervisory board, and the sponsoring institution, confirming compliance with regulatory requirements. The content focuses on updates about the use and timing of raised funds and project progress, which aligns with capital/financing updates rather than a full financial report or earnings release. The document length is about 5,787 characters, which is substantive and not a mere announcement of a report. Therefore, the classification best fitting this document is Capital/Financing Update (CAP).
2022-08-25 Chinese
长春百克生物科技股份公司第五届监事会第五次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the fifth meeting of the fifth Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes the approval of the 2022 semi-annual report, a project delay announcement, and a special report on the use of raised funds. The document itself does not contain the full semi-annual report or detailed financial statements but refers readers to the full reports published on the Shanghai Stock Exchange website. The document length is short (1668 characters) and serves as a formal announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain substantive financial data or the full report text.
2022-08-25 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司部分募投项目延期的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed special verification opinion from CITIC Securities regarding the delay of certain fundraising investment projects of Changchun Baike Biotechnology Co., Ltd. It references regulatory guidelines related to fundraising management and usage, details the fundraising amounts, usage, and reasons for project delays, and includes opinions from the board, supervisory committee, independent directors, and the sponsor institution. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to fundraising project delays, which fits best under the category of Regulatory Filings (RNS) as it does not contain full financial statements or detailed financial results but is a regulatory compliance document.
2022-08-25 Chinese
长春百克生物科技股份公司2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report for comprehensive details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). The document length is 3032 characters, which is sufficient to contain financial data and analysis, not just an announcement or certification. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
长春百克生物科技股份公司2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by Changchun Baike Biotechnology Co., Ltd. It details the amount of funds raised through an IPO, the actual use of these funds during the first half of 2022, the management and storage of these funds, and the status of investment projects funded by these raised funds. The document includes detailed financial figures related to fundraising and usage, as well as compliance with regulatory requirements. This type of report is a specialized disclosure on the use of capital raised by the company, which fits the category of a Capital/Financing Update (CAP) rather than a full annual or interim financial report. It is not an earnings release, audit report, or general regulatory filing. The document length is sufficient and contains substantive financial data about fundraising and capital usage, confirming it is a Capital/Financing Update.
2022-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.